Navigation Links
Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York on Wednesday, February 6, 2008 at 1:00 p.m. ET / 10:00 a.m. PT. Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24...Nasdaq: DCGN ) today announced the approval of all... Court for the District of Delaware,(the "Bankrupt...ition for,relief under Chapter 11 of the United St..., The orders issued by the Bankruptcy Court...
(Date:11/24/2009)..., SEATTLE, Nov. 24 Blue Marble Ene... Odessa Public Development Authority (OPDA) were r...ommunity Economic Revitalization Board (CERB) in a...,s first specialty biochemical biorefinery in Linc...ificantly speed the development of our biorefinery...
(Date:11/24/2009)..., DUBLIN, November 24 /PRNewswire-FirstCall/ ...al specialty biopharmaceutical company, today,anno...Medicines Agency for,velaglucerase alfa, the compa... the treatment of Type 1 Gaucher disease. This is ...alfa that has been submitted, with previous,submis...
(Date:11/24/2009)... Program Connects Customers with Pa...llected with DNA Genotek Products , ... DNA Genotek , a leading provider of products for...reparation, today announced its new global partner...nts for DNA Genotek,s partner community and is des...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ing high purity Type B silica, Tosoh has introduce...e treatment procedures and carbon content levels ,...de range of sample types. , , I... octadecylsilane (ODS) chemistries have been , ...ized properties for select , subsets of c...
... It is well known in HPLC that columns packed wit...at the expense of higher back pressure compared to...The gain in efficiency is usually traded , ...ults in shorter analysis , times and lowe...nes of 5 micron TSK-GEL ODS-100V and ODS-100Z colu...
...public www.dataapex.com , e-mail: vins@dat...V, Bratislava, Slovak Republic, , ...ibution of polymers by the liquid chromatographic ...ectors is a simple, affordable solution for proces...,synthetic and natural polymers. Absolute methods ...
Other Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 3Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 4Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 5
(Date:11/24/2009)...may help gut bacteria bind to the gastrointestinal...ducers to identify strains that are likely to be o...nteract with cells lining the gut to have a benefi... gut they are more likely to stick around long eno...e from the Institute of Food Research. IFR is an ...
(Date:11/24/2009)... -- The Wildlife Conservation Society (WCS) announ...ng population of Siberian tigers has likely declin...g and habitat loss. , WCS says the r...eeds to be done to protect remaining populations o...port was released by the Siberian Tiger Monitoring...
(Date:11/24/2009)..., The presence of increased body fat, and there...he blood, hinders the loss and maintenance of body...versity of Navarra conducted by Estbaliz Goyeneche... The project, entitled "A nutrigenetic and nutrige...ght and inflammation," examines how the individual...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Report shows dramatic decline in Siberian tigers 2It can be predicted the reaction obese patients will have to a diet 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 1Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 3Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 4Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 5Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 6Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 7Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 1Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 2Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 3A young brain for an old bee 9076 1A young brain for an old bee 9076 2
...tiple strains of the flu virus, circulating in a p...nes and create a new virus, one capable of infecti...he open-access journal PLoS Biology. This finding ...which viral strains will attack during upcoming fl..., In the first large-scale effort to sequence the ...
...a clever bit of biology called site-specific recom...to another organism, and perform a sort of graftin...into a chromosome of the target cell. The process ...at cause drug resistance or transmit viruses that ...kemias or other cancers. , But what do the surgeon...
... research on a bacterium that can survive encounte...ned scientists, belief that these plentiful white ... our immune system will permit or prevent bacteria...released today online in The Journal of Immunology...ories (RML), part of the National Institute of All...
Other Biology News:Enlisting genomics to understand flu evolution 2Brown-Harvard team solves mobile DNA's surgical sleight-of-hand 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-GPCR G2A Polyclonal Antibody, Unconjugated from Abcam
Anti-6-keto Prostaglandin F1 alpha (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
BD FACSCanto flow cytometer from BD Biosciences - Immunocytometry Systems
Biology Products: